Haju, Shifa Shaukat
Formulation and evaluation of cilnidipine mucoadhesive buccal film by solvent casting technique for the treatment of hypertension - Vol.13(9) - M P Innovare Academic Sciences Pvt Ltd 2021 - 34-43p.
Objective: Buccal drug deliveryis the most suited route for local as well as systemicdelivery of drugs. Cilnidipineis an L/N type dihydropyridine 4thgeneration calcium channel blocker (CCB), whichdecreases hypertension by blocking the N-type calcium channel to attenuate vascular sympathetic neurotransmission. It has high first-pass metabolismleading to low bioavailability. Hence the present research work was undertaken to formulatemucoadhesivebuccal film of Cilnidipine with an objective to enhance therapeuticefficacy, bioavailabilityand was developed to administer into the unconscious and less-co-operative patients.Methods: Cilnidipine buccal films wereprepared by a solvent-casting techniqueusing various concentrationsof mucoadhesive-polymers such as Hydroxylpropylmethylcellulose(HPMC) E15 andK4Mand ethyl-cellulose as backing-layer, which acts like apatch providing unidirectional drug release. Prepared films were evaluated for their weightvariation, thickness, surface-pH, swelling-index, drug content uniformity, in vitroresidence time, folding endurance, tensile strength, in vitrorelease and permeability studies. Results: Theinfra-red (IR) spectra showed no interaction, and Physico-chemical characteristics were foundwithinthe limit.Swelling of the film increaseswith increasing concentrationof polymers and %drug content of all formulations found to be in the range of 92.13%±0.94% to 97.92%±0.35%.The formulation F5, showed a promisingtensile strength, folding enduranceandin vitrodrug releaseof about 95.18±0.03%, thus can be selected as an optimized formulation of mucoadhesive buccal film.Conclusion: The formulation of Cilnidipine mucoadhesive buccal film was found to be satisfactory and reasonable.
PHARMACEUTICS
Formulation and evaluation of cilnidipine mucoadhesive buccal film by solvent casting technique for the treatment of hypertension - Vol.13(9) - M P Innovare Academic Sciences Pvt Ltd 2021 - 34-43p.
Objective: Buccal drug deliveryis the most suited route for local as well as systemicdelivery of drugs. Cilnidipineis an L/N type dihydropyridine 4thgeneration calcium channel blocker (CCB), whichdecreases hypertension by blocking the N-type calcium channel to attenuate vascular sympathetic neurotransmission. It has high first-pass metabolismleading to low bioavailability. Hence the present research work was undertaken to formulatemucoadhesivebuccal film of Cilnidipine with an objective to enhance therapeuticefficacy, bioavailabilityand was developed to administer into the unconscious and less-co-operative patients.Methods: Cilnidipine buccal films wereprepared by a solvent-casting techniqueusing various concentrationsof mucoadhesive-polymers such as Hydroxylpropylmethylcellulose(HPMC) E15 andK4Mand ethyl-cellulose as backing-layer, which acts like apatch providing unidirectional drug release. Prepared films were evaluated for their weightvariation, thickness, surface-pH, swelling-index, drug content uniformity, in vitroresidence time, folding endurance, tensile strength, in vitrorelease and permeability studies. Results: Theinfra-red (IR) spectra showed no interaction, and Physico-chemical characteristics were foundwithinthe limit.Swelling of the film increaseswith increasing concentrationof polymers and %drug content of all formulations found to be in the range of 92.13%±0.94% to 97.92%±0.35%.The formulation F5, showed a promisingtensile strength, folding enduranceandin vitrodrug releaseof about 95.18±0.03%, thus can be selected as an optimized formulation of mucoadhesive buccal film.Conclusion: The formulation of Cilnidipine mucoadhesive buccal film was found to be satisfactory and reasonable.
PHARMACEUTICS